Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?
Open Access
- 1 October 2013
- journal article
- review article
- Published by Taylor & Francis Ltd in Therapeutics and Clinical Risk Management
- Vol. 9, 361-9
- https://doi.org/10.2147/TCRM.S41552
Abstract
Peer reviewed article authored by (Havla J, Kleiter I, Kümpfel T). Read article or submit your manuscript for publishing.Keywords
This publication has 65 references indexed in Scilit:
- Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trialBMC Neurology, 2013
- Early development of anti-natalizumab antibodies in MS patientsZeitschrift für Neurologie, 2013
- Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringThe Lancet Neurology, 2011
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosisNeurology, 2011
- IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER WITHDRAWAL OF NATALIZUMAB?Neurology, 2010
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: Enigma, wrapped in mystery, enclosed in conundrumAnnals of Neurology, 2009
- Primary central nervous system lymphoma in a patient treated with natalizumabAnnals of Neurology, 2009
- Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyNeurology, 2009